Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. – Hans-Knöll-Institut (HKI)

INCATE was founded in 2021 by leading research institutions, including the Swiss research network NCCR-AntiResist, the University of Basel, the German Center for Infection Research, the InfectControl consortium and the Leibniz-HKI, as well as large pharmaceutical companies (Roche, Shionogi, Boehringer Ingelheim Venture Fund, MSD Germany). INCATE aims to encourage researchers and teams to develop their technologies and products to a level that is attractive to investors or collaborations with Pharma and Biotech companies. We do this by providing advice, community, and funding. The current focus is on therapies, but diagnostics, digital therapies and other modalities will be supported in the future.

The INCATE team consists of individuals associated with partner research institutions who are inspired to work on the challenge of invigorating the pipeline of antimicrobial therapies. The team takes collective responsibility for organization of tasks and responsibilities under the supervision of the INCATE board.